Allogene Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ALLO moving today?
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ALLO.
ALLO insider activity
Allogene Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$603K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | 2026-04-21 | Yoshiyama Annie | Insider | sell | $2.31 | 9,586 | 124,517 | $22K | SEC Form 4 |
| 2026-04-02 | 2026-03-31 | Beneski Benjamin Machinas | Insider | sell | $2.50 | 2,867 | 195,338 | $7K | SEC Form 4 |
| 2026-03-18 | 2026-03-16 | Beneski Benjamin Machinas | Insider | sell | $2.47 | 4,835 | 198,205 | $12K | SEC Form 4 |
| 2026-03-18 | 2026-03-16 | Chang David D | Insider | sell | $2.47 | 47,763 | 5,150,599 | $118K | SEC Form 4 |
| 2026-03-04 | 2026-03-02 | Beneski Benjamin Machinas | Insider | sell | $2.60 | 7,132 | 203,040 | $19K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 9 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moALLO contract awards, year to date.
Public federal awards linked to this ticker.
ALLO lobbying filings, year to date.
Registered lobbying filings matched to Allogene Therapeutics, Inc. Common Stock.